Bristol-Myers Squibb Makes Significant Progress in Psoriatic Arthritis Treatment

Bristol-Myers Squibb Company, a leading pharmaceutical company, has announced promising results from two Phase 3 trials evaluating the effectiveness of its new drug, Sotyktu deucravacitinib, in treating psoriatic arthritis in adults. The trials have shown that Sotyktu hits key endpoints and provides positive outcomes for patients suffering from this debilitating condition. Institutional investors have taken notice of the positive results, with 78% of them investing in Bristol-Myers Squibb. The company's stock, traded under the symbol BMY on NYSE, has been gaining attention in the market. Although this news makes Bristol-Myers Squibb an appealing investment opportunity, it is recommended to seek guidance from professionals at Stocks Prognosis to assess the future movement of the company's stock.